Dashboard
1
Poor Management Efficiency with a low ROCE of 6.26%
- The company has been able to generate a Return on Capital Employed (avg) of 6.26% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -4.19% and Operating profit at 8.12% over the last 5 years
3
Negative results in Sep 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,097 Million (Small Cap)
35.00
NA
0.00%
-0.42
5.18%
0.82
Revenue and Profits:
Net Sales:
139 Million
(Quarterly Results - Sep 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.45%
0%
4.45%
6 Months
-1.25%
0%
-1.25%
1 Year
11.46%
0%
11.46%
2 Years
22.34%
0%
22.34%
3 Years
-2.92%
0%
-2.92%
4 Years
-34.74%
0%
-34.74%
5 Years
0%
0%
0.0%
Zhejiang Benli Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.19%
EBIT Growth (5y)
8.12%
EBIT to Interest (avg)
44.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.50
Tax Ratio
14.19%
Dividend Payout Ratio
32.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.26%
ROE (avg)
4.68%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
1.80
EV to EBIT
33.10
EV to EBITDA
16.02
EV to Capital Employed
2.32
EV to Sales
2.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.02%
ROE (Latest)
5.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
139.00
159.80
-13.02%
Operating Profit (PBDIT) excl Other Income
9.40
24.00
-60.83%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.10
8.90
24.72%
Operating Profit Margin (Excl OI)
67.60%
59.30%
0.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -13.02% vs -11.86% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 24.72% vs -48.55% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
707.20
695.40
1.70%
Operating Profit (PBDIT) excl Other Income
112.20
100.60
11.53%
Interest
0.30
0.90
-66.67%
Exceptional Items
0.50
0.00
Consolidate Net Profit
64.60
59.60
8.39%
Operating Profit Margin (Excl OI)
77.10%
67.50%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.70% vs -8.19% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.39% vs -0.33% in Dec 2023
About Zhejiang Benli Technology Co., Ltd. 
Zhejiang Benli Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






